Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Operating expenses:
Research and development	$ 1,143,178	$ 540,638	$ 4,244,255	$ 4,929,993
General and administrative	1,846,495	1,163,033	4,966,490	3,505,260
Change in fair value of related party note	193,921	180,941	725,932	350,355
Operating loss	(3,183,594)	(1,884,612)	(9,936,677)	(8,785,608)
Other income (expense), net:
Interest income, net	55,151	78,015	69,016	132,995
Other income (expense), net	240,734		(24,496)	330,915
Net loss	$ (2,887,709)	$ (1,806,597)	$ (9,892,157)	$ (8,321,698)
Per common share data:
Basic net loss per common share	$ (0.65)	$ (0.46)	$ (2.39)	$ (2.24)
Diluted net loss per common share	$ (0.65)	$ (0.46)	$ (2.39)	$ (2.24)
Weighted average number of common shares outstanding, basic	4,443,262	3,953,370	4,131,831	3,711,507
Weighted average number of common shares outstanding, diluted	4,443,262	3,953,370	4,131,831	3,711,507
Other comprehensive income (loss):
Foreign currency translation gain (loss)	$ 27,204	$ (61,463)	$ (60,538)	$ (241,891)
Comprehensive loss	$ (2,860,505)	$ (1,868,060)	$ (9,952,695)	$ (8,563,589)